nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—CYP2D6—Vinorelbine—ovarian cancer	0.0307	0.255	CbGbCtD
Escitalopram—CYP3A4—Topotecan—ovarian cancer	0.0277	0.23	CbGbCtD
Escitalopram—CYP3A4—Vinorelbine—ovarian cancer	0.0195	0.162	CbGbCtD
Escitalopram—CYP3A4—Paclitaxel—ovarian cancer	0.0137	0.114	CbGbCtD
Escitalopram—CYP2D6—Doxorubicin—ovarian cancer	0.0116	0.0964	CbGbCtD
Escitalopram—CYP3A4—Docetaxel—ovarian cancer	0.0099	0.0823	CbGbCtD
Escitalopram—CYP3A4—Doxorubicin—ovarian cancer	0.00738	0.0613	CbGbCtD
Escitalopram—Citalopram—ABCB1—ovarian cancer	0.00513	1	CrCbGaD
Escitalopram—Oedema—Docetaxel—ovarian cancer	0.000246	0.000296	CcSEcCtD
Escitalopram—Weight increased—Doxorubicin—ovarian cancer	0.000246	0.000295	CcSEcCtD
Escitalopram—Epistaxis—Epirubicin—ovarian cancer	0.000245	0.000295	CcSEcCtD
Escitalopram—Infection—Docetaxel—ovarian cancer	0.000244	0.000294	CcSEcCtD
Escitalopram—Weight decreased—Doxorubicin—ovarian cancer	0.000244	0.000294	CcSEcCtD
Escitalopram—Sinusitis—Epirubicin—ovarian cancer	0.000244	0.000293	CcSEcCtD
Escitalopram—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000243	0.000293	CcSEcCtD
Escitalopram—Agranulocytosis—Epirubicin—ovarian cancer	0.000243	0.000292	CcSEcCtD
Escitalopram—Pneumonia—Doxorubicin—ovarian cancer	0.000242	0.000291	CcSEcCtD
Escitalopram—Shock—Docetaxel—ovarian cancer	0.000242	0.000291	CcSEcCtD
Escitalopram—Nervous system disorder—Docetaxel—ovarian cancer	0.000241	0.00029	CcSEcCtD
Escitalopram—Thrombocytopenia—Docetaxel—ovarian cancer	0.000241	0.00029	CcSEcCtD
Escitalopram—Infestation NOS—Doxorubicin—ovarian cancer	0.000241	0.000289	CcSEcCtD
Escitalopram—Infestation—Doxorubicin—ovarian cancer	0.000241	0.000289	CcSEcCtD
Escitalopram—Tachycardia—Docetaxel—ovarian cancer	0.00024	0.000289	CcSEcCtD
Escitalopram—Feeling abnormal—Paclitaxel—ovarian cancer	0.000239	0.000288	CcSEcCtD
Escitalopram—Skin disorder—Docetaxel—ovarian cancer	0.000239	0.000287	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000239	0.000287	CcSEcCtD
Escitalopram—Bradycardia—Epirubicin—ovarian cancer	0.000238	0.000286	CcSEcCtD
Escitalopram—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000237	0.000285	CcSEcCtD
Escitalopram—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000236	0.000284	CcSEcCtD
Escitalopram—Haemoglobin—Epirubicin—ovarian cancer	0.000235	0.000282	CcSEcCtD
Escitalopram—Stomatitis—Doxorubicin—ovarian cancer	0.000235	0.000282	CcSEcCtD
Escitalopram—Jaundice—Doxorubicin—ovarian cancer	0.000235	0.000282	CcSEcCtD
Escitalopram—Anorexia—Docetaxel—ovarian cancer	0.000234	0.000282	CcSEcCtD
Escitalopram—Rhinitis—Epirubicin—ovarian cancer	0.000234	0.000281	CcSEcCtD
Escitalopram—Conjunctivitis—Doxorubicin—ovarian cancer	0.000234	0.000281	CcSEcCtD
Escitalopram—Urinary tract infection—Doxorubicin—ovarian cancer	0.000234	0.000281	CcSEcCtD
Escitalopram—Haemorrhage—Epirubicin—ovarian cancer	0.000233	0.000281	CcSEcCtD
Escitalopram—Hepatitis—Epirubicin—ovarian cancer	0.000233	0.000281	CcSEcCtD
Escitalopram—Hypoaesthesia—Epirubicin—ovarian cancer	0.000232	0.000279	CcSEcCtD
Escitalopram—Pharyngitis—Epirubicin—ovarian cancer	0.000232	0.000279	CcSEcCtD
Escitalopram—Sweating—Doxorubicin—ovarian cancer	0.000231	0.000277	CcSEcCtD
Escitalopram—Urinary tract disorder—Epirubicin—ovarian cancer	0.000231	0.000277	CcSEcCtD
Escitalopram—Urticaria—Paclitaxel—ovarian cancer	0.00023	0.000277	CcSEcCtD
Escitalopram—Oedema peripheral—Epirubicin—ovarian cancer	0.00023	0.000277	CcSEcCtD
Escitalopram—Hypotension—Docetaxel—ovarian cancer	0.00023	0.000276	CcSEcCtD
Escitalopram—Haematuria—Doxorubicin—ovarian cancer	0.000229	0.000276	CcSEcCtD
Escitalopram—Connective tissue disorder—Epirubicin—ovarian cancer	0.000229	0.000276	CcSEcCtD
Escitalopram—Body temperature increased—Paclitaxel—ovarian cancer	0.000229	0.000276	CcSEcCtD
Escitalopram—Abdominal pain—Paclitaxel—ovarian cancer	0.000229	0.000276	CcSEcCtD
Escitalopram—Urethral disorder—Epirubicin—ovarian cancer	0.000229	0.000275	CcSEcCtD
Escitalopram—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000228	0.000274	CcSEcCtD
Escitalopram—Epistaxis—Doxorubicin—ovarian cancer	0.000227	0.000273	CcSEcCtD
Escitalopram—Sinusitis—Doxorubicin—ovarian cancer	0.000226	0.000272	CcSEcCtD
Escitalopram—Visual impairment—Epirubicin—ovarian cancer	0.000225	0.000271	CcSEcCtD
Escitalopram—Agranulocytosis—Doxorubicin—ovarian cancer	0.000225	0.00027	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000224	0.000269	CcSEcCtD
Escitalopram—Insomnia—Docetaxel—ovarian cancer	0.000222	0.000268	CcSEcCtD
Escitalopram—Paraesthesia—Docetaxel—ovarian cancer	0.000221	0.000266	CcSEcCtD
Escitalopram—Erythema multiforme—Epirubicin—ovarian cancer	0.000221	0.000265	CcSEcCtD
Escitalopram—Bradycardia—Doxorubicin—ovarian cancer	0.00022	0.000264	CcSEcCtD
Escitalopram—Dyspnoea—Docetaxel—ovarian cancer	0.000219	0.000264	CcSEcCtD
Escitalopram—Somnolence—Docetaxel—ovarian cancer	0.000219	0.000263	CcSEcCtD
Escitalopram—Eye disorder—Epirubicin—ovarian cancer	0.000218	0.000262	CcSEcCtD
Escitalopram—Tinnitus—Epirubicin—ovarian cancer	0.000218	0.000262	CcSEcCtD
Escitalopram—Haemoglobin—Doxorubicin—ovarian cancer	0.000217	0.000261	CcSEcCtD
Escitalopram—Flushing—Epirubicin—ovarian cancer	0.000217	0.000261	CcSEcCtD
Escitalopram—Cardiac disorder—Epirubicin—ovarian cancer	0.000217	0.000261	CcSEcCtD
Escitalopram—Rhinitis—Doxorubicin—ovarian cancer	0.000217	0.00026	CcSEcCtD
Escitalopram—Dyspepsia—Docetaxel—ovarian cancer	0.000216	0.00026	CcSEcCtD
Escitalopram—Hepatitis—Doxorubicin—ovarian cancer	0.000216	0.00026	CcSEcCtD
Escitalopram—Haemorrhage—Doxorubicin—ovarian cancer	0.000216	0.00026	CcSEcCtD
Escitalopram—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000215	0.000259	CcSEcCtD
Escitalopram—Pharyngitis—Doxorubicin—ovarian cancer	0.000214	0.000258	CcSEcCtD
Escitalopram—Decreased appetite—Docetaxel—ovarian cancer	0.000214	0.000257	CcSEcCtD
Escitalopram—Hypersensitivity—Paclitaxel—ovarian cancer	0.000214	0.000257	CcSEcCtD
Escitalopram—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000213	0.000257	CcSEcCtD
Escitalopram—Oedema peripheral—Doxorubicin—ovarian cancer	0.000213	0.000256	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000212	0.000255	CcSEcCtD
Escitalopram—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000212	0.000255	CcSEcCtD
Escitalopram—Fatigue—Docetaxel—ovarian cancer	0.000212	0.000255	CcSEcCtD
Escitalopram—Angiopathy—Epirubicin—ovarian cancer	0.000212	0.000255	CcSEcCtD
Escitalopram—Urethral disorder—Doxorubicin—ovarian cancer	0.000212	0.000255	CcSEcCtD
Escitalopram—Immune system disorder—Epirubicin—ovarian cancer	0.000211	0.000254	CcSEcCtD
Escitalopram—Mediastinal disorder—Epirubicin—ovarian cancer	0.00021	0.000253	CcSEcCtD
Escitalopram—Pain—Docetaxel—ovarian cancer	0.00021	0.000253	CcSEcCtD
Escitalopram—Constipation—Docetaxel—ovarian cancer	0.00021	0.000253	CcSEcCtD
Escitalopram—Chills—Epirubicin—ovarian cancer	0.000209	0.000252	CcSEcCtD
Escitalopram—Arrhythmia—Epirubicin—ovarian cancer	0.000209	0.000251	CcSEcCtD
Escitalopram—Visual impairment—Doxorubicin—ovarian cancer	0.000208	0.00025	CcSEcCtD
Escitalopram—Asthenia—Paclitaxel—ovarian cancer	0.000208	0.00025	CcSEcCtD
Escitalopram—Alopecia—Epirubicin—ovarian cancer	0.000206	0.000248	CcSEcCtD
Escitalopram—Pruritus—Paclitaxel—ovarian cancer	0.000205	0.000247	CcSEcCtD
Escitalopram—Mental disorder—Epirubicin—ovarian cancer	0.000205	0.000246	CcSEcCtD
Escitalopram—Erythema multiforme—Doxorubicin—ovarian cancer	0.000204	0.000246	CcSEcCtD
Escitalopram—Malnutrition—Epirubicin—ovarian cancer	0.000203	0.000244	CcSEcCtD
Escitalopram—Erythema—Epirubicin—ovarian cancer	0.000203	0.000244	CcSEcCtD
Escitalopram—Feeling abnormal—Docetaxel—ovarian cancer	0.000203	0.000244	CcSEcCtD
Escitalopram—Eye disorder—Doxorubicin—ovarian cancer	0.000202	0.000243	CcSEcCtD
Escitalopram—Tinnitus—Doxorubicin—ovarian cancer	0.000201	0.000242	CcSEcCtD
Escitalopram—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000201	0.000242	CcSEcCtD
Escitalopram—Flushing—Doxorubicin—ovarian cancer	0.0002	0.000241	CcSEcCtD
Escitalopram—Cardiac disorder—Doxorubicin—ovarian cancer	0.0002	0.000241	CcSEcCtD
Escitalopram—Flatulence—Epirubicin—ovarian cancer	0.0002	0.000241	CcSEcCtD
Escitalopram—Tension—Epirubicin—ovarian cancer	0.000199	0.00024	CcSEcCtD
Escitalopram—Dysgeusia—Epirubicin—ovarian cancer	0.000199	0.000239	CcSEcCtD
Escitalopram—Diarrhoea—Paclitaxel—ovarian cancer	0.000198	0.000239	CcSEcCtD
Escitalopram—Nervousness—Epirubicin—ovarian cancer	0.000197	0.000237	CcSEcCtD
Escitalopram—Back pain—Epirubicin—ovarian cancer	0.000197	0.000236	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—ovarian cancer	0.000196	0.000236	CcSEcCtD
Escitalopram—Muscle spasms—Epirubicin—ovarian cancer	0.000195	0.000235	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—ovarian cancer	0.000195	0.000235	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000195	0.000234	CcSEcCtD
Escitalopram—Abdominal pain—Docetaxel—ovarian cancer	0.000194	0.000234	CcSEcCtD
Escitalopram—Body temperature increased—Docetaxel—ovarian cancer	0.000194	0.000234	CcSEcCtD
Escitalopram—Chills—Doxorubicin—ovarian cancer	0.000194	0.000233	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—ovarian cancer	0.000193	0.000232	CcSEcCtD
Escitalopram—Dizziness—Paclitaxel—ovarian cancer	0.000192	0.000231	CcSEcCtD
Escitalopram—Vision blurred—Epirubicin—ovarian cancer	0.000192	0.00023	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—ovarian cancer	0.000191	0.00023	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—ovarian cancer	0.000189	0.000228	CcSEcCtD
Escitalopram—Ill-defined disorder—Epirubicin—ovarian cancer	0.000189	0.000227	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—ovarian cancer	0.000188	0.000226	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—ovarian cancer	0.000188	0.000226	CcSEcCtD
Escitalopram—Anaemia—Epirubicin—ovarian cancer	0.000188	0.000226	CcSEcCtD
Escitalopram—Agitation—Epirubicin—ovarian cancer	0.000187	0.000225	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—ovarian cancer	0.000185	0.000223	CcSEcCtD
Escitalopram—Tension—Doxorubicin—ovarian cancer	0.000185	0.000222	CcSEcCtD
Escitalopram—Vomiting—Paclitaxel—ovarian cancer	0.000184	0.000222	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—ovarian cancer	0.000184	0.000221	CcSEcCtD
Escitalopram—Malaise—Epirubicin—ovarian cancer	0.000183	0.00022	CcSEcCtD
Escitalopram—Rash—Paclitaxel—ovarian cancer	0.000183	0.00022	CcSEcCtD
Escitalopram—Dermatitis—Paclitaxel—ovarian cancer	0.000183	0.00022	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—ovarian cancer	0.000183	0.00022	CcSEcCtD
Escitalopram—Vertigo—Epirubicin—ovarian cancer	0.000183	0.00022	CcSEcCtD
Escitalopram—Syncope—Epirubicin—ovarian cancer	0.000182	0.000219	CcSEcCtD
Escitalopram—Leukopenia—Epirubicin—ovarian cancer	0.000182	0.000219	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—ovarian cancer	0.000182	0.000219	CcSEcCtD
Escitalopram—Headache—Paclitaxel—ovarian cancer	0.000182	0.000219	CcSEcCtD
Escitalopram—Hypersensitivity—Docetaxel—ovarian cancer	0.000181	0.000218	CcSEcCtD
Escitalopram—Muscle spasms—Doxorubicin—ovarian cancer	0.000181	0.000217	CcSEcCtD
Escitalopram—Palpitations—Epirubicin—ovarian cancer	0.00018	0.000216	CcSEcCtD
Escitalopram—Loss of consciousness—Epirubicin—ovarian cancer	0.000179	0.000215	CcSEcCtD
Escitalopram—Cough—Epirubicin—ovarian cancer	0.000177	0.000213	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—ovarian cancer	0.000177	0.000213	CcSEcCtD
Escitalopram—Asthenia—Docetaxel—ovarian cancer	0.000176	0.000212	CcSEcCtD
Escitalopram—Convulsion—Epirubicin—ovarian cancer	0.000176	0.000212	CcSEcCtD
Escitalopram—Hypertension—Epirubicin—ovarian cancer	0.000175	0.000211	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000174	0.00021	CcSEcCtD
Escitalopram—Pruritus—Docetaxel—ovarian cancer	0.000174	0.000209	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—ovarian cancer	0.000174	0.000209	CcSEcCtD
Escitalopram—Arthralgia—Epirubicin—ovarian cancer	0.000173	0.000208	CcSEcCtD
Escitalopram—Chest pain—Epirubicin—ovarian cancer	0.000173	0.000208	CcSEcCtD
Escitalopram—Myalgia—Epirubicin—ovarian cancer	0.000173	0.000208	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—ovarian cancer	0.000173	0.000208	CcSEcCtD
Escitalopram—Anxiety—Epirubicin—ovarian cancer	0.000172	0.000207	CcSEcCtD
Escitalopram—Nausea—Paclitaxel—ovarian cancer	0.000172	0.000207	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000172	0.000207	CcSEcCtD
Escitalopram—Discomfort—Epirubicin—ovarian cancer	0.000171	0.000206	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—ovarian cancer	0.00017	0.000204	CcSEcCtD
Escitalopram—Dry mouth—Epirubicin—ovarian cancer	0.000169	0.000204	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—ovarian cancer	0.000169	0.000203	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—ovarian cancer	0.000169	0.000203	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—ovarian cancer	0.000168	0.000202	CcSEcCtD
Escitalopram—Diarrhoea—Docetaxel—ovarian cancer	0.000168	0.000202	CcSEcCtD
Escitalopram—Confusional state—Epirubicin—ovarian cancer	0.000167	0.000201	CcSEcCtD
Escitalopram—Palpitations—Doxorubicin—ovarian cancer	0.000166	0.0002	CcSEcCtD
Escitalopram—Oedema—Epirubicin—ovarian cancer	0.000166	0.000199	CcSEcCtD
Escitalopram—Anaphylactic shock—Epirubicin—ovarian cancer	0.000166	0.000199	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—ovarian cancer	0.000165	0.000199	CcSEcCtD
Escitalopram—Infection—Epirubicin—ovarian cancer	0.000165	0.000198	CcSEcCtD
Escitalopram—Cough—Doxorubicin—ovarian cancer	0.000164	0.000197	CcSEcCtD
Escitalopram—Shock—Epirubicin—ovarian cancer	0.000163	0.000196	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—ovarian cancer	0.000163	0.000196	CcSEcCtD
Escitalopram—Nervous system disorder—Epirubicin—ovarian cancer	0.000163	0.000196	CcSEcCtD
Escitalopram—Dizziness—Docetaxel—ovarian cancer	0.000163	0.000196	CcSEcCtD
Escitalopram—Thrombocytopenia—Epirubicin—ovarian cancer	0.000162	0.000195	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—ovarian cancer	0.000162	0.000195	CcSEcCtD
Escitalopram—Tachycardia—Epirubicin—ovarian cancer	0.000162	0.000195	CcSEcCtD
Escitalopram—Skin disorder—Epirubicin—ovarian cancer	0.000161	0.000194	CcSEcCtD
Escitalopram—Hyperhidrosis—Epirubicin—ovarian cancer	0.00016	0.000193	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—ovarian cancer	0.00016	0.000193	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—ovarian cancer	0.00016	0.000193	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—ovarian cancer	0.00016	0.000193	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—ovarian cancer	0.00016	0.000192	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000159	0.000191	CcSEcCtD
Escitalopram—Discomfort—Doxorubicin—ovarian cancer	0.000158	0.00019	CcSEcCtD
Escitalopram—Anorexia—Epirubicin—ovarian cancer	0.000158	0.00019	CcSEcCtD
Escitalopram—Dry mouth—Doxorubicin—ovarian cancer	0.000157	0.000188	CcSEcCtD
Escitalopram—Vomiting—Docetaxel—ovarian cancer	0.000156	0.000188	CcSEcCtD
Escitalopram—Rash—Docetaxel—ovarian cancer	0.000155	0.000186	CcSEcCtD
Escitalopram—Hypotension—Epirubicin—ovarian cancer	0.000155	0.000186	CcSEcCtD
Escitalopram—Dermatitis—Docetaxel—ovarian cancer	0.000155	0.000186	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—ovarian cancer	0.000155	0.000186	CcSEcCtD
Escitalopram—Headache—Docetaxel—ovarian cancer	0.000154	0.000185	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—ovarian cancer	0.000153	0.000185	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000153	0.000185	CcSEcCtD
Escitalopram—Infection—Doxorubicin—ovarian cancer	0.000152	0.000183	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000151	0.000182	CcSEcCtD
Escitalopram—Shock—Doxorubicin—ovarian cancer	0.000151	0.000182	CcSEcCtD
Escitalopram—Nervous system disorder—Doxorubicin—ovarian cancer	0.00015	0.000181	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00015	0.000181	CcSEcCtD
Escitalopram—Insomnia—Epirubicin—ovarian cancer	0.00015	0.00018	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—ovarian cancer	0.00015	0.00018	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—ovarian cancer	0.000149	0.000179	CcSEcCtD
Escitalopram—Paraesthesia—Epirubicin—ovarian cancer	0.000149	0.000179	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000148	0.000178	CcSEcCtD
Escitalopram—Dyspnoea—Epirubicin—ovarian cancer	0.000148	0.000178	CcSEcCtD
Escitalopram—Somnolence—Epirubicin—ovarian cancer	0.000147	0.000177	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—ovarian cancer	0.000146	0.000176	CcSEcCtD
Escitalopram—Nausea—Docetaxel—ovarian cancer	0.000146	0.000176	CcSEcCtD
Escitalopram—Dyspepsia—Epirubicin—ovarian cancer	0.000146	0.000176	CcSEcCtD
Escitalopram—Decreased appetite—Epirubicin—ovarian cancer	0.000144	0.000173	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—ovarian cancer	0.000143	0.000172	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000143	0.000172	CcSEcCtD
Escitalopram—Fatigue—Epirubicin—ovarian cancer	0.000143	0.000172	CcSEcCtD
Escitalopram—Pain—Epirubicin—ovarian cancer	0.000142	0.000171	CcSEcCtD
Escitalopram—Constipation—Epirubicin—ovarian cancer	0.000142	0.000171	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00014	0.000168	CcSEcCtD
Escitalopram—Insomnia—Doxorubicin—ovarian cancer	0.000139	0.000167	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—ovarian cancer	0.000138	0.000166	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—ovarian cancer	0.000137	0.000165	CcSEcCtD
Escitalopram—Feeling abnormal—Epirubicin—ovarian cancer	0.000137	0.000164	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—ovarian cancer	0.000136	0.000164	CcSEcCtD
Escitalopram—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000136	0.000163	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—ovarian cancer	0.000135	0.000162	CcSEcCtD
Escitalopram—Decreased appetite—Doxorubicin—ovarian cancer	0.000133	0.00016	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000132	0.000159	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—ovarian cancer	0.000132	0.000159	CcSEcCtD
Escitalopram—Urticaria—Epirubicin—ovarian cancer	0.000132	0.000158	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—ovarian cancer	0.000131	0.000158	CcSEcCtD
Escitalopram—Pain—Doxorubicin—ovarian cancer	0.000131	0.000158	CcSEcCtD
Escitalopram—Abdominal pain—Epirubicin—ovarian cancer	0.000131	0.000158	CcSEcCtD
Escitalopram—Body temperature increased—Epirubicin—ovarian cancer	0.000131	0.000158	CcSEcCtD
Escitalopram—Feeling abnormal—Doxorubicin—ovarian cancer	0.000126	0.000152	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000125	0.000151	CcSEcCtD
Escitalopram—Hypersensitivity—Epirubicin—ovarian cancer	0.000122	0.000147	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—ovarian cancer	0.000122	0.000147	CcSEcCtD
Escitalopram—Abdominal pain—Doxorubicin—ovarian cancer	0.000121	0.000146	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—ovarian cancer	0.000121	0.000146	CcSEcCtD
Escitalopram—Asthenia—Epirubicin—ovarian cancer	0.000119	0.000143	CcSEcCtD
Escitalopram—Pruritus—Epirubicin—ovarian cancer	0.000117	0.000141	CcSEcCtD
Escitalopram—Diarrhoea—Epirubicin—ovarian cancer	0.000113	0.000136	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—ovarian cancer	0.000113	0.000136	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—ovarian cancer	0.00011	0.000132	CcSEcCtD
Escitalopram—Dizziness—Epirubicin—ovarian cancer	0.00011	0.000132	CcSEcCtD
Escitalopram—Pruritus—Doxorubicin—ovarian cancer	0.000109	0.000131	CcSEcCtD
Escitalopram—Vomiting—Epirubicin—ovarian cancer	0.000105	0.000127	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—ovarian cancer	0.000105	0.000126	CcSEcCtD
Escitalopram—Rash—Epirubicin—ovarian cancer	0.000105	0.000126	CcSEcCtD
Escitalopram—Dermatitis—Epirubicin—ovarian cancer	0.000104	0.000126	CcSEcCtD
Escitalopram—Headache—Epirubicin—ovarian cancer	0.000104	0.000125	CcSEcCtD
Escitalopram—Dizziness—Doxorubicin—ovarian cancer	0.000101	0.000122	CcSEcCtD
Escitalopram—Nausea—Epirubicin—ovarian cancer	9.85e-05	0.000118	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—ovarian cancer	9.76e-05	0.000117	CcSEcCtD
Escitalopram—Rash—Doxorubicin—ovarian cancer	9.68e-05	0.000116	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—ovarian cancer	9.67e-05	0.000116	CcSEcCtD
Escitalopram—Headache—Doxorubicin—ovarian cancer	9.61e-05	0.000116	CcSEcCtD
Escitalopram—Nausea—Doxorubicin—ovarian cancer	9.11e-05	0.00011	CcSEcCtD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CD—ovarian cancer	1.68e-05	0.000389	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CD—ovarian cancer	1.67e-05	0.000388	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—YAP1—ovarian cancer	1.65e-05	0.000383	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CD—ovarian cancer	1.65e-05	0.000382	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—CXCL8—ovarian cancer	1.62e-05	0.000376	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.61e-05	0.000373	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.61e-05	0.000373	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.56e-05	0.000362	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—IL2—ovarian cancer	1.55e-05	0.000359	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CB—ovarian cancer	1.53e-05	0.000355	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PPP2R1A—ovarian cancer	1.53e-05	0.000355	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PPP2R1A—ovarian cancer	1.53e-05	0.000354	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CD—ovarian cancer	1.53e-05	0.000353	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CD—ovarian cancer	1.52e-05	0.000352	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PPP2R1A—ovarian cancer	1.5e-05	0.000348	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CD—ovarian cancer	1.5e-05	0.000347	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CXCL8—ovarian cancer	1.47e-05	0.000342	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—FASN—ovarian cancer	1.46e-05	0.000339	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CB—ovarian cancer	1.46e-05	0.000339	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CB—ovarian cancer	1.46e-05	0.000338	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC5A5—ovarian cancer	1.44e-05	0.000334	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CB—ovarian cancer	1.44e-05	0.000333	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL2—ovarian cancer	1.41e-05	0.000326	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CXCL8—ovarian cancer	1.41e-05	0.000326	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TERT—ovarian cancer	1.4e-05	0.000325	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CXCL8—ovarian cancer	1.4e-05	0.000325	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC2A1—ovarian cancer	1.39e-05	0.000322	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CXCL8—ovarian cancer	1.38e-05	0.00032	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.36e-05	0.000316	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—FASN—ovarian cancer	1.35e-05	0.000312	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—IL2—ovarian cancer	1.34e-05	0.000311	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—IL2—ovarian cancer	1.34e-05	0.00031	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP1B1—ovarian cancer	1.33e-05	0.000309	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CB—ovarian cancer	1.33e-05	0.000308	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CB—ovarian cancer	1.33e-05	0.000307	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.33e-05	0.000307	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—IL2—ovarian cancer	1.32e-05	0.000306	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CB—ovarian cancer	1.3e-05	0.000302	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CAV1—ovarian cancer	1.3e-05	0.000301	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.28e-05	0.000296	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CXCL8—ovarian cancer	1.28e-05	0.000296	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CXCL8—ovarian cancer	1.27e-05	0.000295	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CXCL8—ovarian cancer	1.25e-05	0.00029	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ESR1—ovarian cancer	1.25e-05	0.00029	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL6ST—ovarian cancer	1.23e-05	0.000285	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.23e-05	0.000284	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL2—ovarian cancer	1.22e-05	0.000283	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL2—ovarian cancer	1.22e-05	0.000282	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TERT—ovarian cancer	1.22e-05	0.000282	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TERT—ovarian cancer	1.21e-05	0.000281	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL2—ovarian cancer	1.2e-05	0.000278	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TERT—ovarian cancer	1.19e-05	0.000277	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.18e-05	0.000274	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—APC—ovarian cancer	1.18e-05	0.000274	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CG—ovarian cancer	1.18e-05	0.000274	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—NRAS—ovarian cancer	1.18e-05	0.000274	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.18e-05	0.000273	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—MAPK3—ovarian cancer	1.13e-05	0.000262	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CAV1—ovarian cancer	1.13e-05	0.000261	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CAV1—ovarian cancer	1.12e-05	0.00026	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CAV1—ovarian cancer	1.1e-05	0.000256	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.1e-05	0.000254	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.09e-05	0.000252	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ESR1—ovarian cancer	1.08e-05	0.000251	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ESR1—ovarian cancer	1.08e-05	0.00025	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—YAP1—ovarian cancer	1.08e-05	0.00025	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TYMS—ovarian cancer	1.08e-05	0.00025	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—MAPK1—ovarian cancer	1.08e-05	0.00025	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—ovarian cancer	1.08e-05	0.00025	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6ST—ovarian cancer	1.07e-05	0.000247	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ESR1—ovarian cancer	1.06e-05	0.000246	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6ST—ovarian cancer	1.06e-05	0.000246	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6ST—ovarian cancer	1.05e-05	0.000242	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CD—ovarian cancer	1.04e-05	0.000241	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CA—ovarian cancer	1.03e-05	0.000239	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—APC—ovarian cancer	1.03e-05	0.000237	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CG—ovarian cancer	1.03e-05	0.000237	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—NRAS—ovarian cancer	1.03e-05	0.000237	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—APC—ovarian cancer	1.02e-05	0.000237	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CG—ovarian cancer	1.02e-05	0.000237	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—NRAS—ovarian cancer	1.02e-05	0.000237	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	1.02e-05	0.000236	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.01e-05	0.000234	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CG—ovarian cancer	1.01e-05	0.000233	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—APC—ovarian cancer	1.01e-05	0.000233	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—NRAS—ovarian cancer	1.01e-05	0.000233	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TYMS—ovarian cancer	9.92e-06	0.00023	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—MAPK3—ovarian cancer	9.82e-06	0.000227	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—MAPK3—ovarian cancer	9.79e-06	0.000227	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—MAPK3—ovarian cancer	9.63e-06	0.000223	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	9.35e-06	0.000217	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—MAPK1—ovarian cancer	9.34e-06	0.000216	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—ovarian cancer	9.34e-06	0.000216	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—MAPK1—ovarian cancer	9.31e-06	0.000216	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—ovarian cancer	9.31e-06	0.000216	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	9.19e-06	0.000213	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	9.17e-06	0.000212	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	9.16e-06	0.000212	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	9.06e-06	0.00021	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MTOR—ovarian cancer	9.06e-06	0.00021	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CD—ovarian cancer	9.01e-06	0.000209	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CD—ovarian cancer	8.98e-06	0.000208	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—ovarian cancer	8.93e-06	0.000207	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	8.9e-06	0.000206	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	8.84e-06	0.000205	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—ovarian cancer	8.82e-06	0.000204	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—FASN—ovarian cancer	8.81e-06	0.000204	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—ovarian cancer	8.79e-06	0.000204	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	8.76e-06	0.000203	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	8.71e-06	0.000202	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CAV1—ovarian cancer	8.69e-06	0.000201	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC5A5—ovarian cancer	8.66e-06	0.000201	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	8.66e-06	0.000201	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	8.65e-06	0.0002	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	8.51e-06	0.000197	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	8.41e-06	0.000195	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC2A1—ovarian cancer	8.37e-06	0.000194	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—ovarian cancer	8.34e-06	0.000193	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL2—ovarian cancer	8.32e-06	0.000193	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.31e-06	0.000192	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL6—ovarian cancer	8.28e-06	0.000192	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—ovarian cancer	8.12e-06	0.000188	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—ovarian cancer	8.11e-06	0.000188	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—ovarian cancer	8.08e-06	0.000187	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	8.04e-06	0.000186	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP1B1—ovarian cancer	8.02e-06	0.000186	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CAV1—ovarian cancer	8e-06	0.000185	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—ovarian cancer	7.96e-06	0.000184	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	7.95e-06	0.000184	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—ovarian cancer	7.93e-06	0.000184	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CG—ovarian cancer	7.92e-06	0.000183	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MMP9—ovarian cancer	7.88e-06	0.000183	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	7.85e-06	0.000182	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MTOR—ovarian cancer	7.85e-06	0.000182	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—ovarian cancer	7.83e-06	0.000181	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MTOR—ovarian cancer	7.83e-06	0.000181	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CB—ovarian cancer	7.83e-06	0.000181	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	7.81e-06	0.000181	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	7.71e-06	0.000179	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	7.71e-06	0.000179	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	7.64e-06	0.000177	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL8—ovarian cancer	7.55e-06	0.000175	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL8—ovarian cancer	7.52e-06	0.000174	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRAS—ovarian cancer	7.5e-06	0.000174	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRAS—ovarian cancer	7.47e-06	0.000173	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	7.41e-06	0.000172	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	7.37e-06	0.000171	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	7.36e-06	0.00017	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	7.35e-06	0.00017	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	7.29e-06	0.000169	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CG—ovarian cancer	7.28e-06	0.000169	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	7.27e-06	0.000168	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	7.23e-06	0.000168	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—ovarian cancer	7.22e-06	0.000167	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL2—ovarian cancer	7.21e-06	0.000167	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—ovarian cancer	7.2e-06	0.000167	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL2—ovarian cancer	7.19e-06	0.000167	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL6—ovarian cancer	7.18e-06	0.000166	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	7.16e-06	0.000166	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL6—ovarian cancer	7.15e-06	0.000166	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	7.11e-06	0.000165	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	7.09e-06	0.000164	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL2—ovarian cancer	7.08e-06	0.000164	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	7.07e-06	0.000164	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	7.04e-06	0.000163	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—ovarian cancer	7.03e-06	0.000163	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—ovarian cancer	7.01e-06	0.000162	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—STAT3—ovarian cancer	7.01e-06	0.000162	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NRAS—ovarian cancer	6.99e-06	0.000162	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	6.96e-06	0.000161	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CD—ovarian cancer	6.96e-06	0.000161	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	6.94e-06	0.000161	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	6.9e-06	0.00016	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	6.83e-06	0.000158	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MMP9—ovarian cancer	6.83e-06	0.000158	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MMP9—ovarian cancer	6.81e-06	0.000158	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—ovarian cancer	6.79e-06	0.000157	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—ovarian cancer	6.77e-06	0.000157	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	6.7e-06	0.000155	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	6.69e-06	0.000155	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	6.66e-06	0.000154	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT1—ovarian cancer	6.62e-06	0.000153	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—ovarian cancer	6.61e-06	0.000153	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	6.6e-06	0.000153	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—ovarian cancer	6.51e-06	0.000151	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	6.5e-06	0.000151	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMS—ovarian cancer	6.49e-06	0.00015	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CD—ovarian cancer	6.4e-06	0.000148	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	6.37e-06	0.000148	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—ovarian cancer	6.37e-06	0.000147	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—ovarian cancer	6.13e-06	0.000142	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	6.11e-06	0.000142	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STAT3—ovarian cancer	6.07e-06	0.000141	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CB—ovarian cancer	6.07e-06	0.000141	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NRAS—ovarian cancer	6.06e-06	0.00014	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STAT3—ovarian cancer	6.05e-06	0.00014	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NRAS—ovarian cancer	6.04e-06	0.00014	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	6.02e-06	0.000139	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—ovarian cancer	6.01e-06	0.000139	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	5.96e-06	0.000138	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	5.94e-06	0.000138	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK3—ovarian cancer	5.8e-06	0.000134	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	5.78e-06	0.000134	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	5.69e-06	0.000132	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—ovarian cancer	5.64e-06	0.000131	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—ovarian cancer	5.62e-06	0.00013	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CB—ovarian cancer	5.58e-06	0.000129	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—ovarian cancer	5.53e-06	0.000128	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	5.53e-06	0.000128	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK1—ovarian cancer	5.52e-06	0.000128	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—ovarian cancer	5.52e-06	0.000128	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	5.5e-06	0.000127	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—ovarian cancer	5.5e-06	0.000127	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	5.41e-06	0.000125	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	5.41e-06	0.000125	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—ovarian cancer	5.35e-06	0.000124	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—ovarian cancer	5.24e-06	0.000121	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CAV1—ovarian cancer	5.23e-06	0.000121	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—ovarian cancer	5.21e-06	0.000121	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—ovarian cancer	5.19e-06	0.00012	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	5.11e-06	0.000118	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRAS—ovarian cancer	5.11e-06	0.000118	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL6—ovarian cancer	4.89e-06	0.000113	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—ovarian cancer	4.82e-06	0.000112	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	4.79e-06	0.000111	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	4.77e-06	0.000111	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.76e-06	0.00011	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	4.7e-06	0.000109	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—ovarian cancer	4.63e-06	0.000107	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—ovarian cancer	4.62e-06	0.000107	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—ovarian cancer	4.55e-06	0.000105	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT1—ovarian cancer	4.51e-06	0.000105	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRAS—ovarian cancer	4.43e-06	0.000103	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRAS—ovarian cancer	4.42e-06	0.000102	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	4.35e-06	0.000101	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6—ovarian cancer	4.24e-06	9.82e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6—ovarian cancer	4.23e-06	9.79e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.19e-06	9.7e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6—ovarian cancer	4.16e-06	9.64e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT1—ovarian cancer	3.91e-06	9.06e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT1—ovarian cancer	3.9e-06	9.03e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3.84e-06	8.89e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—ovarian cancer	3.7e-06	8.57e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.65e-06	8.45e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.4e-06	7.88e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—ovarian cancer	3.15e-06	7.3e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKT1—ovarian cancer	3.02e-06	7e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKT1—ovarian cancer	2.78e-06	6.44e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.22e-06	5.15e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKT1—ovarian cancer	1.82e-06	4.21e-05	CbGpPWpGaD
